Loading organizations...
§ Public · Laguna Hills, CA, USA
Medical device company developing Ultra-Low Temperature Cryoablation (ULTC) technologies for cardiac electrophysiology, treating arrhythmias.
Based in Laguna Hills, California, Adagio Medical is a medical device company that develops and commercializes catheter-based ultra-low temperature cryoablation technologies to treat complex cardiac arrhythmias. The enterprise operates with a workforce of 21 to 50 employees and manufactures proprietary catheter systems designed to create continuous, transmural lesions in diseased cardiac tissue. In July 2024, the company transitioned to the public equity markets and listed on the Nasdaq exchange under the ticker ADGM following a business combination with ARYA Sciences Acquisition Corp IV. This SPAC merger was sponsored by Perceptive Advisors and raised approximately $84.2 million in gross capital, valuing the combined entity at roughly $128 million at the time of the announcement. Backed by early incubator Fjord Ventures, the organization was originally founded in 2011 by Olav Bergheim and James L. Cox.
Adagio Medical has raised $64.5M across 3 funding rounds.
Adagio Medical has raised $64.5M in total across 3 funding rounds.
Adagio Medical has raised $64.5M across 3 funding rounds. Most recently, it raised $19.0M Other Equity in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 20, 2025 | $19M Venture Round | — | — | Announced |
| Nov 1, 2020 | $43M Series E | — | Tuan Huynh, Fjord Ventures, JMR Capital, Perceptive Advisors, Zach Scheiner | Announced |
| Apr 3, 2013 | $2.5M Venture Round | — | — | Announced |
Adagio Medical is a medical device company specializing in the development of advanced cryoablation technologies to treat cardiac arrhythmias such as atrial fibrillation, atrial flutter, and ventricular tachycardia. Its flagship product leverages proprietary Ultra Low Temperature Cryoablation (ULTC) technology designed to create large, durable lesions that extend through the full thickness of cardiac tissue, improving treatment efficacy. The company primarily serves cardiologists and electrophysiologists by providing innovative tools to address complex heart rhythm disorders, aiming to improve patient outcomes and procedural efficiency[1][4][5][6].
Founded in 2020 and headquartered in Laguna Hills, California, Adagio Medical emerged from the need for more effective and durable ablation solutions in cardiac care. The company quickly gained traction by advancing its ULTC technology into clinical and commercial stages, including regulatory approvals and market introduction in the European Union. This early progress positioned Adagio as a promising innovator in the cardiac ablation space[1][3][4].
Adagio Medical is riding the trend of increasing demand for minimally invasive, effective cardiac arrhythmia treatments driven by the rising prevalence of atrial fibrillation and other rhythm disorders globally. Advances in cryoablation technology align with broader healthcare trends emphasizing precision medicine and improved patient safety. The timing is favorable due to growing awareness of arrhythmia-related morbidity and healthcare systems seeking cost-effective interventions. Adagio’s innovations contribute to evolving electrophysiology practices and may influence standards of care by offering an alternative to traditional ablation techniques[1][4][6].
Looking ahead, Adagio Medical is poised to expand its market presence by advancing clinical evidence, pursuing additional regulatory clearances, and broadening its product portfolio. Trends such as an aging population and increasing incidence of cardiac arrhythmias will likely drive demand for its technologies. The company’s ability to demonstrate superior clinical outcomes and cost-effectiveness will be critical to its influence and growth in the cardiac device sector. Continued innovation in cryoablation could position Adagio as a key player shaping the future of cardiac arrhythmia treatment[1][4][6].
Adagio Medical has raised $64.5M in total across 3 funding rounds.
Adagio Medical's investors include Tuan Huynh, Fjord Ventures, JMR Capital, Perceptive Advisors, Zach Scheiner.